Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), reported unaudited financial results for the third quarter ended Dec. 31, 2025, underscoring continued advancement in its key clinical programs. The company highlighted progress across its HLP003 Phase 3 program for major depressive disorder (MDD) and HLP004 Phase 2 program for generalized anxiety disorder (GAD), along with a completed leadership transition and corporate rebranding.
Helus Pharma ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026. The financial results reflect the company's commitment to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—to address large unmet needs in mental health.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, another proprietary NSA, is in Phase 2 for GAD. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For more details, the full press release is available at https://ibn.fm/VigPf. Investors can stay updated on company news via the newsroom at https://ibn.fm/HELP.
This announcement matters because it provides a snapshot of Helus Pharma's financial health and clinical progress, which are critical for investors and stakeholders monitoring the development of novel treatments for depression and anxiety. The company's strong cash position and advancing pipeline suggest potential for significant clinical data readouts in 2026, which could impact the mental health treatment landscape if results are positive.
